What Is Medical Weight Management?
Medical weight management is a coordinated, supervised approach to treating excess weight and obesity using clinical methods. Unlike fad diets or one-size-fits-all programs, evidence-based medical management integrates prescription medications, tailored nutrition, behavioral modification, and—when appropriate—adjunctive treatments. The primary aim is not just weight reduction, but sustainable health improvement, addressing root causes and comorbidities.
In recent years, a breakthrough class of medications has changed the landscape: GLP-1 receptor agonists, most notably Wegovy (semaglutide). For the first time, patients are seeing sustained, meaningful weight loss previously unattainable with older therapies.
How Does Wegovy Work?
Wegovy contains semaglutide, a synthetic analog of the human hormone GLP-1 (glucagon-like peptide-1). After a once-weekly injection, semaglutide acts on brain receptors to reduce appetite, increase satiety, and alter food intake. Clinical studies show it also slows gastric emptying, helping patients feel fuller, longer.
- Dosing: Wegovy starts at 0.25 mg weekly, ramping up to 2.4 mg over several months. Full dosing details.
- Route: Subcutaneous injection, primarily in the abdomen or thigh.
- Safety: All dosing changes should be directed by a healthcare provider.
Unlike short-term treatments, semaglutide is designed for chronic use. But like all medications, it works best as part of a holistic approach—combining medication, nutrition, physical activity, and behavioral support.
Who Is Eligible for Wegovy and GLP-1 Therapy?
Not everyone qualifies for prescription weight loss medications. Physicians use strict criteria, typically based on body mass index (BMI) and the presence of weight-related health problems:
- BMI ≥ 30 kg/m² (obesity), or
- BMI ≥ 27 kg/m² with conditions such as type 2 diabetes, hypertension, or sleep apnea
- No history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2
- Thorough evaluation of medication history, kidney and liver function, and cardiovascular status
Individual eligibility is always confirmed by a qualified healthcare professional. For an expanded perspective on who benefits most, review our guide to obesity medication selection criteria.
Benefits Beyond the Scale
The primary goal for many patients is improved numbers on the scale. But modern weight management delivers more. In clinical trials, Wegovy users experienced:
- Greater reduction in body weight (average 10–15% over 68 weeks)
- Improved A1C and blood glucose for those with type 2 diabetes
- Lowered blood pressure and cholesterol in many users
- Enhanced energy, mobility, and quality of life
Results aren’t uniform. Some patients achieve dramatic changes, others more modest. Combining Wegovy with sustained lifestyle adjustments—nutritional counseling, physical activity, and psychological support—yields the best long-term outcomes.
Our Wegovy weight loss breakdown includes before–after charts and comparative results from the STEP trials (the gold standard for semaglutide research).
Potential Risks & Side Effects
Common Side Effects
- Nausea and gastrointestinal discomfort (most frequent, often transient)
- Diarrhea or constipation
- Headache and mild dizziness
- Injection site reactions
Most symptoms subside after the first weeks. Hydration, slow dose escalation, and dietary adjustments can help minimize discomfort.
Serious Risks
- Pancreatitis (rare but requires prompt medical attention)
- Gallbladder disease
- Risk of thyroid C-cell tumors in susceptible individuals
- Potential hypoglycemia, especially in patients on other diabetes drugs
Always review family thyroid history and discuss any unusual abdominal pain with your care team.
How Does Wegovy Compare to Other Options?
The advent of GLP-1 medications like semaglutide has transformed medical weight management. Compared to older therapies, average weight loss is higher and sustained:
- Wegovy (semaglutide): 10–15% body weight reduction
- Older options (orlistat, phentermine/topiramate): 3–8% on average
The trade-off is that GLP-1s, including semaglutide and other GLP-1s, require ongoing injections and can cause digestive side effects. Still, the clinical impact is unmatched for many.
FAQs and Real-World Experience
Patients and clinicians alike have practical questions about what to expect, how to prepare, and what it’s like to use Wegovy in daily life. Our FAQ below addresses the five most frequent and clinically relevant topics, drawn from patient interviews and direct clinical feedback.